These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

461 related items for PubMed ID: 26938635

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. HbA1c Outcomes in Patients Treated With Canagliflozin Versus Sitagliptin in US Health Plans.
    Thayer S, Aguilar R, Korrer S, Chow W.
    Clin Ther; 2017 Oct; 39(10):2061-2072. PubMed ID: 28943114
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records.
    Wysham CH, Lefebvre P, Pilon D, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Duh MS, Ingham M.
    J Diabetes Complications; 2019 Feb; 33(2):140-147. PubMed ID: 30554838
    [Abstract] [Full Text] [Related]

  • 7. Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States.
    Cai J, Divino V, Burudpakdee C.
    Curr Med Res Opin; 2017 Jul; 33(7):1317-1328. PubMed ID: 28418262
    [Abstract] [Full Text] [Related]

  • 8. Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting.
    Buysman EK, Chow W, Henk HJ, Rupnow MF.
    Curr Med Res Opin; 2015 Jan; 31(1):137-43. PubMed ID: 25356602
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Real-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin-an electronic health-record-based study.
    Lefebvre P, Pilon D, Robitaille MN, Lafeuille MH, Chow W, Pfeifer M, Duh MS.
    Curr Med Res Opin; 2016 Jun; 32(6):1151-9. PubMed ID: 27115475
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Canagliflozin treatment of Hispanic and non-Hispanic patients with type 2 diabetes in a US managed care setting.
    Chow W, Buysman E, Rupnow MF, Aguilar R, Henk HJ.
    Curr Med Res Opin; 2016 Jun; 32(1):13-22. PubMed ID: 26414434
    [Abstract] [Full Text] [Related]

  • 14. Retrospective Study on the Impact of Adherence in Achieving Glycemic Goals in Type 2 Diabetes Mellitus Patients Receiving Canagliflozin.
    Buysman EK, Anderson A, Bacchus S, Ingham M.
    Adv Ther; 2017 Apr; 34(4):937-953. PubMed ID: 28251556
    [Abstract] [Full Text] [Related]

  • 15. Glycemic Control Outcomes After Canagliflozin Initiation: Observations in a Medicare and Commercial Managed Care Population in Clinical Practice.
    Bailey RA, Schwab P, Xu Y, Pasquale M, Renda A.
    Clin Ther; 2016 Sep; 38(9):2046-2057.e2. PubMed ID: 27567160
    [Abstract] [Full Text] [Related]

  • 16. An observational study of glycemic control in canagliflozin treated patients.
    Meckley LM, Miyasato G, Kokkotos F, Bumbaugh J, Bailey RA.
    Curr Med Res Opin; 2015 Aug; 31(8):1479-86. PubMed ID: 25986535
    [Abstract] [Full Text] [Related]

  • 17. Economic simulation of canagliflozin and sitagliptin treatment outcomes in patients with type 2 diabetes mellitus with inadequate glycemic control.
    Lafeuille MH, Grittner AM, Gravel J, Bailey RA, Martin S, Garber L, Duh MS, Lefebvre P.
    J Med Econ; 2015 Feb; 18(2):113-25. PubMed ID: 25350645
    [Abstract] [Full Text] [Related]

  • 18. Real-world evaluation of Hba1c, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin: an analysis of electronic medical records from a network of hospitals in Florida.
    Tanton D, Duh MS, Lafeuille MH, Lefebvre P, Pilon D, Zhdanava M, Emond B, Inman D, Bailey RA.
    Curr Med Res Opin; 2018 Jun; 34(6):1099-1115. PubMed ID: 29468896
    [Abstract] [Full Text] [Related]

  • 19. Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study.
    Fushimi Y, Obata A, Sanada J, Iwamoto Y, Mashiko A, Horiya M, Mizoguchi-Tomita A, Nishioka M, Kan Y, Kinoshita T, Okauchi S, Hirukawa H, Kohara K, Tatsumi F, Shimoda M, Nakanishi S, Mune T, Kaku K, Kaneto H.
    J Diabetes Res; 2020 Jun; 2020():4861681. PubMed ID: 32337293
    [Abstract] [Full Text] [Related]

  • 20. Dulaglutide Shows Sustained Reduction in Glycosylated Hemoglobin Values: 2-Year US Real-world Study Results.
    Mody R, Yu M, Grabner M, Boye K, Teng CC, Kwan AYM.
    Clin Ther; 2020 Nov; 42(11):2184-2195. PubMed ID: 33256915
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.